8-K: Intelligent Bio Solutions Reports Strong Revenue Growth in Preliminary Q3 Results

Intelligent Bio Solutions Inc. announced a significant 80% year-over-year revenue increase for the fiscal third quarter and a 193% increase for the nine months ended March 31, 2024.

Summary

• Intelligent Bio Solutions Inc. reported preliminary unaudited revenue of approximately $0.82 million for the three months ended March 31, 2024.
• This represents an 80% increase compared to the same period in the prior year.
• The company also reported approximately $2.38 million in revenue for the nine months ended March 31, 2024, a 193% increase year-over-year.
• Cartridge sales are expected to increase by 17% and reader sales by 20% for the quarter.
• The company achieved its highest quarterly cartridge sales since acquiring Intelligent Fingerprinting Limited in 2022.
• Cartridge and reader sales are expected to increase 25% and 63%, respectively, from July 1, 2023, through to March 31, 2024, compared to the same period the prior year.
• The company expects to release full financial results in its upcoming Quarterly Report on Form 10-Q, expected to be filed during the week commencing May 6, 2024.

Sentiment

Score: 8

Explanation: The document presents a very positive outlook with strong revenue growth and increasing sales. The company's technology is gaining market traction, and management is optimistic about the future. However, the results are preliminary and unaudited, which introduces a small element of uncertainty.

Positives

• The company's revenue growth is substantial, with an 80% increase in the third quarter and a 193% increase over nine months.
• The company is seeing strong growth in both cartridge and reader sales.
• The company's technology is gaining market traction, as evidenced by the increased sales and adoption of their drug screening solutions.
• The company's fingerprint sweat-based technology is addressing the need for comprehensive drug testing solutions.

Negatives

• The reported revenue figures are preliminary and unaudited, and are subject to adjustments.
• The company's financial results are based on information available to management as of the date of the press release.

Risks

• The company's ability to successfully develop and commercialize its drug and diagnostic tests is subject to risks and uncertainties.
• The company's ability to realize commercial benefits from its partnerships and collaborations is not guaranteed.
• The company's ability to secure regulatory approvals is subject to risks and uncertainties.
• The company's forward-looking statements are only predictions and involve known and unknown risks, uncertainties, and other factors.

Future Outlook

The company expects to disclose full financial results for the fiscal third quarter and nine months ended March 31, 2024, in its upcoming Quarterly Report on Form 10-Q, expected to be filed with the Securities and Exchange Commission during the week commencing May 6, 2024.

Management Comments

• Harry Simeonidis, President and CEO, stated that the preliminary unaudited revenue results, with consistent year-over-year growth, is a clear indicator of the strength of their proprietary fingerprint sweat-based technology in the market.
• Management believes that their Intelligent Fingerprinting Drug Screening Solution is addressing the challenges associated with drug use and supporting safety and well-being across workplaces, law enforcement and healthcare.

Industry Context

The announcement highlights the growing need for rapid and non-invasive drug testing solutions, particularly in response to the rise of synthetic drugs like methamphetamine and fentanyl. This positions Intelligent Bio Solutions as a key player in the market, addressing the demand for comprehensive drug testing in various sectors.

Comparison to Industry Standards

• While specific competitor data is not provided in the document, the 80% and 193% revenue growth figures suggest a strong performance compared to industry averages for medical technology companies in the drug testing sector.
• The company's focus on fingerprint sweat analysis for drug testing is a unique approach, differentiating it from traditional methods and potentially giving it a competitive edge.
• The company's claim of the highest quarterly cartridge sales since the acquisition of Intelligent Fingerprinting Limited in 2022 indicates a successful integration and growth trajectory.

Stakeholder Impact

• Shareholders will likely view the strong revenue growth positively.
• Employees may benefit from the company's growth and success.
• Customers will have access to innovative drug testing solutions.
• Suppliers may see increased demand for their products and services.
• Creditors may view the company as a lower risk due to its strong financial performance.

Next Steps

• The company will file its Quarterly Report on Form 10-Q with the Securities and Exchange Commission during the week commencing May 6, 2024.
• The company will continue to develop and commercialize its drug and diagnostic tests.

Key Dates

Keywords

Intelligent Bio Solutions, revenue, drug testing, fingerprint, cartridge sales, reader sales, medical technology, biosensor, non-invasive testing, sweat analysis